Drug Treatment Validation of Functional Magnetic Resonance Imaging in Generalized Anxiety Disorder

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

32 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-04-30

Study Completion Date

2009-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to find out how an anti-anxiety drug or placebo affects the activity of your brain when you are at rest and when you are viewing emotional material, such as, emotional faces and pictures.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Processes and Circuitry Underlying Threat Sensitivity as a Treatment Target for Co-morbid Anxiety and Depression

NCT06004115

Depression, Anxiety Fear Depression +3 more

RECRUITING PHASE4

Neuroimaging of Pavlovian Fear Conditioning Processes in Patients With Pathological Anxiety

NCT03498599

Post Traumatic Stress Disorder Anxiety Disorders Panic Disorder +2 more

UNKNOWN NA

A Long-Term Study Continuing on From Study 04-001-01 of an Experimental Medication in Adults With Anxiety Disorder

NCT00106860

Anxiety Disorder

COMPLETED PHASE3

Experimental Medication For the Treatment of Generalized Anxiety Disorder

NCT00097708

Anxiety Disorder

COMPLETED PHASE3

Neurobiology of Generalized Fear-Conditioning & Avoidance in Anxiety Disorders

NCT03033056

Anxiety Disorders

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is an exploratory study to evaluate the usefulness of fMRI as a biomarker to measure the response to a known, FDA approved marketed anxiolytic. As such, this is not a study testing safety and efficacy of an approved medicine; it is a study to evaluate the usefulness of fMRI (a non-significant risk device procedure) to correlate the clinical/behavioral effects of a marketed anxiolytic with brain activity assessed by magnetic resonance imaging. fMRI is a more direct measure of brain function than behavior, outcomes are quantitative and objective. As such, it may be more specific, i.e., may be more sensitive to drug effects or show them earlier than clinical endpoints and enable determination of efficacy in smaller or shorter studies than those required to show effects on clinical endpoints. Finally, imaging may allow differentiation of placebo responders from true drug responders.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Generalized Anxiety Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

alprazolam

Alprazolam, an FDA-approved drug, will be administered to 24 patients with generalized anxiety disorder.

Group Type EXPERIMENTAL

Alprazolam (Xanax)

Intervention Type DRUG

Drug dose will be fixed across patients: alprazolam 0.5 mg b.i.d escalating to 1.0 mg b.i.d. The treatment duration will be approximately 28 days (4 weeks).

placebo

A placebo comparator will be administered to 12 patients with generalized anxiety disorder

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo, bid, p.o. for 28 +/- 2 days.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Alprazolam (Xanax)

Drug dose will be fixed across patients: alprazolam 0.5 mg b.i.d escalating to 1.0 mg b.i.d. The treatment duration will be approximately 28 days (4 weeks).

Intervention Type DRUG

Placebo

Placebo, bid, p.o. for 28 +/- 2 days.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Xanax

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or female between 18 - 65 years of age, inclusive
2. In good general health (as determined by medical history, physical examination, laboratory assessments and electrocardiogram (ECG)), especially no findings (including concomitant medications) that would constitute contraindications for treatment with alprazolam
3. Diagnostic and Statistical Manual-IV criteria for Generalized Anxiety Disorder (GAD) (exception: at least 3 months of symptoms)
4. Hamilton Anxiety Scale at screening \>/= 20
5. Montgomery-Asberg Depression Rating Scale (MADRS) at screening \< 25
6. Prior medications washout:

* 2-week medication washout prior to randomization for most psychotropic medications
* If prior history of fluoxetine use, this drug must have been discontinued at least 5 weeks before randomization
7. For females of non-childbearing potential: either postmenopausal for the past year (confirmed by an follicle stimulating hormone level greater than 40 mIU/mL unless the subject is receiving hormone replacement therapy), or surgically sterile (e.g., tubal ligation, hysterectomy)
8. Males and female subjects of child-bearing potential may be included if using appropriate contraceptive methods:

* must use abstinence or two methods of contraception throughout the trial:

* should include one primary (e.g., systemic hormonal contraception, vasectomy of the male partner) AND one secondary barrier method (e.g., latex condoms, spermicide) OR
* a double barrier method (e.g., latex condom plus spermicide (foam, suppository, gel, cream)) may be used
9. GAD should be the clinically predominant disorder, as judged by the investigator, considering relative severity and impact on functioning

Exclusion Criteria

1. Axis I disorder other than stated above with the exception of the following permitted comorbidities:

* history of (within past 6 months) or current dysthymia
* current (within past 6 months) depressive episode with MADRS at baseline \< 25
* history of major depression as long as no current depressive episode as defined above
2. Drug or alcohol dependence in the past 6 months
3. Positive urine toxicology (drugs of abuse as determined by clinician's assessment of positive urine test)
4. Active suicidal ideation (determined by clinician)
5. For females of childbearing potential: Pregnancy or intent to become pregnant or currently breastfeeding
6. Current use of beta-blockers or stimulants (e.g., Methylphenidate, d-Amphetamine, modafinil, and illicit drugs like cocaine or 3,4-methylenedioxy-N-methylamphetamine \[MDMA\])
7. Current regular use of antihistamines (except for inhalants which are permitted)
8. Current use of herbal medication for mood or anxiety disorders and unwillingness to discontinue use for the duration of the study
9. Current use of fluoxetine
10. Concomitant psychotropic medications including regular use of sleeping medications (also herbals)

* occasional use of sleeping medication, with the exception of benzodiazepines, is permitted as long as it is not taken the evening prior to a visit
11. Past intolerance (including allergic) to, or clear history of non-response to the study medication
12. Current smoker (\> 10 cigarettes/day); habitual caffeine consumption of more than 400 mg/d (approximately 4 cups of coffee or equivalent)
13. Body mass index \> 32.5 kg/m2
14. Contraindication to magnetic resonance imaging based on a standard fMRI screening forms
15. Concurrent participation in an institutional review board (IRB) approved investigational drug trial
16. Any other reason why, per clinician, the patient should not participate in this study (to be included in this assessment are all considerations, warnings, precautions as per current FDA-approved drug label for Xanax®)

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No